Publications by authors named "D M Wingerchuk"
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.
Neurol Neuroimmunol Neuroinflamm
January 2025
Article Synopsis
- The study analyzes how often and in what way the cerebellum is affected during attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), which isn't fully covered by current diagnostic standards.
- Out of 432 AQP4+NMOSD patients, 17 (4%) showed cerebellar attacks with severe neurological symptoms, including high disability scores.
- MRI results indicated that most cerebellar lesions were found in the cerebellar peduncles and dentate nucleus, with many persisting beyond six months, suggesting that understanding these patterns is important for refining future diagnostic criteria for AQP4+NMOSD.
Background: Inebilizumab, an anti-CD19 B-cell-depleting antibody, demonstrated safety and efficacy in neuromyelitis optica spectrum disorder in the randomised controlled period of the N-MOmentum trial. Here, end-of-study data, including the randomised controlled period and open-label extension period, are reported.
Methods: In the double-blind, randomised, placebo-controlled, phase 2/3 N-MOmentum trial, adults aged 18 years and older with an neuromyelitis optica spectrum disorder diagnosis, Expanded Disability Status Scale score of 8·0 or less, and history of either at least one acute inflammatory attack requiring rescue therapy in the past year or two attacks requiring rescue therapy in the past 2 years, were recruited from 81 outpatient specialty clinics or hospitals in 24 countries.
Objective: This study was undertaken to investigate factors associated with aquaporin-4 (AQP4)-IgG serostatus change using a large serological database.
Methods: This retrospective study utilizes Mayo Clinic Neuroimmunology Laboratory data from 2007 to 2021. We included all patients with ≥2 AQP4-IgG tests (by cell-based assay).
Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD).
Objective: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum.
Methods: Adults ( = 230) with NMOSD and Expanded Disability Status Scale score ⩽8 were randomized (3:1) to inebilizumab 300 mg or placebo.